TP63 and cancer: With progression from normal to LGSIL, six genes (SPRR1B, CNFN, TP63, PAX2, SCEL, S100A7) were enriched in cancer pathways including GO:0030855, epithelial cell differentiation (adj p ≤ 7.4 E-3), and GO:0008544, epidermis development (adj p = 0.05).